• Home
  • Leadership
    • Management Team
    • Advisors
    • Scientific Advisory Board
    • Board of Directors
  • Therapeutic Programs
  • Media
  • Contact
Rare Disease Advisor – An Interview with Damon Race, President and CEO of GeneVentiv Therapeutics

Rare Disease Advisor – An Interview with Damon Race, President and CEO of GeneVentiv Therapeutics

by Damon Race | Aug 29, 2023 | In the News

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics.  The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
UNC-Chapel Hill gene therapy spinout raises $1.4 million

UNC-Chapel Hill gene therapy spinout raises $1.4 million

by Damon Race | Sep 12, 2022 | In the News

By Zac Ezzone  –  Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
UNC-Chapel Hill gene therapy spinout raises $1.4 million

Bootstrapped UNC spinout lands $300K for gene therapy work

by Damon Race | Jun 14, 2022 | In the News

The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone – Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In...
Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center

Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center

by Damon Race | Jun 8, 2022 | In the News

Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
GeneVentiv Therapeutics Wins KickStart Commercialization Grant

GeneVentiv Therapeutics Wins KickStart Commercialization Grant

by Damon Race | Mar 17, 2022 | In the News

Shar March 16, 2022 By Shellie Edge KickStart Venture Services – the premier life sciences startup program and accelerator from Innovate Carolina – has awarded commercialization grants to two UNC-affiliated startup companies, Elipsys, LLC, and GeneVentiv Therapeutics,...
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect

GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect

by Damon Race | Mar 8, 2022 | In the News

Startup Spotlight: Presenting companies to pitch at CED’s Venture...
« Older Entries

Recent Posts

  • GeneVentiv Invited to Present at BioPharm America 2023
  • Rare Disease Advisor – An Interview with Damon Race, President and CEO of GeneVentiv Therapeutics
  • GeneVentiv Welcomes New Advisors
  • GeneVentiv Invited to Present in Labcorp’s Symposium at the 26th Annual Meeting of the American Society of Cell and Gene Therapy
  • GeneVentiv Invited to Present at The National Hemophilia Foundation’s 17th Workshop

Recent Comments

    Archives

    • August 2023
    • April 2023
    • February 2023
    • January 2023
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • November 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020

    Categories

    • In the News
    • Press
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    • Please prove you are human by selecting the Cup.
    • This field is for validation purposes and should be left unchanged.

    Copyright © 2020 GeneVentiv Therapeutics. All rights reserved.